GlobeNewsWire
21 Nov 2025, 14:01 UTC · 43w ago
Verdict
Headline takes no side. We score MAIA +0.80 across five claims — strongly bullish.
+0.80strongly bullish
More positive than 84% of ticker scores this week
What the story claims
5 claims · scored −1 bearish … +1 bullish
MAIA reported an observed overall survival (OS) of 17.8 months in the THIO-101 Phase 2 trial for third-line NSCLC patients.
So whatThis significantly exceeds the cited 6-month standard OS for this patient population, suggesting strong potential for a breakthrough therapy.
More positive than 99% of claims this week
A single patient in the THIO-101 Phase 2 trial has demonstrated survival of 30 months.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
More positive than 85% of claims this week
MAIA has commenced patient screening for the Phase 3 THIO-104 clinical trial.
More positive than 76% of claims this week
The Phase 2 THIO-101 expansion trial has enrolled 12 patients to date and expanded sites into EMA countries, Turkey, and Taiwan.
More positive than 48% of claims this week
The FDA has granted Fast Track designation for ateganosine for the treatment of NSCLC.
More positive than 48% of claims this week
Which stocks this story touches
More positive than 84% of ticker scores this week
Company reports steady progress in Phase 2 expansion, commencement of Phase 3 screening, and strong overall survival data for its lead candidate ateganosine.
More positive than 43% of ticker scores this week
The company's drug Libtayo is mentioned as part of the treatment regimen in clinical trials, which may provide supporting evidence for its use in combination therapies.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
+52.7%
Price agrees with the score
$1.33 vs $0.8710 close before publication (Nov 20) · not market-adjusted
MAIA chart →